Smith & Nephew, for a start.
Why? Because there is a growing expectation the US Federal Trade Commission will soon (possibly as early as this week) make up its mind on whether it will give the green light to Zimmer's purchase of rival Biomet for $13.4 billion.
Here is a link to Wall Street Journal article on the topic:
http://www.wsj.com/articles/zimmer-extends-termination-date-for-biomet-deal-1428961625
Word is Stryker - which last year looked at buying the London-listed orthopaedic device manufacturer - was never to going to revisit its interest in Smith & Nephew until the US-based group sees whether Zimmer's acquisition of Biomet is cleared by regulators.
Thanks for your information about the US federal trade commission. I have very well to understand your article.quality thesis
ReplyDelete